Ting‐Chao Chou
About
In The Last Decade
Ting‐Chao Chou
343 papers receiving 28.5k citations
Hit Papers
Peers
Comparison fields: 5 of 179
- Molecular Biology 14.1k
- Oncology 8.1k
- Organic Chemistry 4.2k
- Infectious Diseases 2.9k
- Virology 2.8k
Countries citing papers authored by Ting‐Chao Chou
This map shows the geographic impact of Ting‐Chao Chou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ting‐Chao Chou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ting‐Chao Chou more than expected).
Fields of papers citing papers by Ting‐Chao Chou
This network shows the impact of papers produced by Ting‐Chao Chou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ting‐Chao Chou. The network helps show where Ting‐Chao Chou may publish in the future.
Co-authorship network of co-authors of Ting‐Chao Chou
This figure shows the co-authorship network connecting the top 25 collaborators of Ting‐Chao Chou. A scholar is included among the top collaborators of Ting‐Chao Chou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ting‐Chao Chou. Ting‐Chao Chou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 6 | |
| 3 | 6 | |
| 4 | Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. | 158 |
| 5 | 34 | |
| 6 | Iso-oxazole-Fludelone (KOS-1803) as a potent and efficacious microtubule-stablization epothilone against xenograft tumors. | 1 |
| 7 | The mass-action law-based new computer software, CompuSyn, for automated simulation of synergism and antagonism in drug combination studies | 11 |
| 8 | Design, experimentation and computerized automated data analysis of synergistic drug combinations against xenograft tumors by Taxotere and T900607 | 7 |
| 9 | 20 | |
| 10 | Synthesis and biological activity of AHMA-EDTA conjugates | 1 |
| 11 | 44 | |
| 12 | The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice. | 42 |
| 13 | Synergistic interactions of cyclosporine, rapamycin, and brequinar on heart allograft survival in mice. | 3 |
| 14 | 85 | |
| 15 | 10 | |
| 16 | 7 | |
| 17 | 74 | |
| 18 | Conservation of laboratory animals by improved experimental design, generalized equations and computer analysis | 2 |
| 19 | Kinetic and biochemical modulation of pyrimidine antimetabolites in therapy of acute leukemia | 1 |
| 20 | Comparison of the mass action law with the power law the probit law and the logit law in dose effect analyses | 4 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.